Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next
Dec. 22, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” into a deal-driven stock, after BioMarin Pharmaceutical announced an all-cash agreement to acquire Amicus for $14.50 per share. With shares trading around $14.18